The Future Of Drug Discovery Is 4 Billion Years Old (Viswa Colluru, Founder & CEO at Enveda)
The GeneralistShow Notes
For decades, drug discovery has shifted away from nature and toward biology-first approaches. Viswa Colluru believes that shift was a catastrophic mistake. His company, Enveda Biosciences, has raised over $500 million to build a “search engine for nature’s chemistry.” The mission is personal: he grew up around his father’s pharmacy in India and later lost his mother to a treatable cancer whose medicine his family couldn’t afford. Many life-changing medicines, including morphine, aspirin, and metformin, originated in nature, but there has never been a reliable, scalable way to systematically explore its chemistry. Colluru founded Enveda in 2019 with $55,000 of his own savings to change that. The company has since identified 18 drug candidates, with three now in clinical trials.
In our conversation, we explore: Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) How Enveda built a system to decode unknown molecules in nature The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work Why old ideas, from immunotherapy to natural products, often hold the most latent potential How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis Why first-in-class medicines capture the vast majority of returns in pharma What competitive table tennis taught him about building companies — Thank you to the partners who make this possible Brex: The intelligent finance platform. Ahrefs Brand Radar: Find your brand in AI results. Persona: Trusted identity verification for any use case. — Timestamps (00:00) Introduction to Viswa Colluru (03:57) His father’s pharmacy and early exposure to Western and Ayurvedic medicine (07:06) Early pull toward technology (09:29) His mother’s leukemia diagnosis (14:24) Studying Biotechnology (16:07) Graduate school (17:55) Studying immunotherapy when it was unfashionable (24:23) Innovation vs. novelty (27:24) Lessons from table tennis (32:05) Joining Recursion (37:10) Learning urgency and courage (40:42) What launched Enveda (45:40) The limits of reductionist drug discovery (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:04:30) Three categories of leading drugs: Eczema, obesity, ulcerative colitis (1:13:27) Why GLP-1s are not the whole answer (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation — Follow Viswa Colluru LinkedIn: https://www.linkedin.com/in/viswacolluru X: https://x.com/viswacolluru — Resources and episode mentions: https://www.generalist.com/p/the-future-of-drug-discovery — Production and marketing by penname.co. For inquiries about sponsoring the podcast, email [email protected].
More from The Generalist
Pete Florence and I began by agreeing that his company has an excellent name. Generalist builds AI for robots, including models that can begin learning a new task from a single demonstration. We talked about dexterity, the strange business of gathering physical experience for a machine, and what we might build if robots could do much more of the work. — Every timestamp 00:00 Intro 02:24 GEN-1.5 and one-shot learning 08:55 What makes a task difficult 10:53 Dexterity in robotics 14:53 Matt Mason’s definition of a hand 17:34 Giving robots a sense of touch 20:30 Growing up in a family of technologists and scientists 22:46 What drew Pete into robotics 27:38 Generalist’s founding thesis and what sets it apart 32:17 Protecting simplicity 35:01 How Generalist’s data collection has evolved 35:30 Generalist’s scaling philosophy 39:53 Generalist’s build-versus-buy philosophy 42:15 Balancing general intelligence with commercial deployment 44:24 Why Pete is betting on dexterity 47:33 The durability of the robotics application layer 49:09 Open-weight robotics models and data flywheels 50:52 Geopolitics, safety, and alignment 52:42 The parallels between teaching humans and robots 1:00:05 The timeline for robotics progress and adoption 1:03:37 Book recommendations — Transcript: https://www.generalist.com/i/220756708/transcript — Pete’s complete reading list The Score Takes Care of Itself: My Philosophy of Leadership: https://www.amazon.com/Score-Takes-Care-Itself-Philosophy/dp/1591843472 Wooden on Leadership: How to Create a Winning Organization: https://www.amazon.com/Wooden-Leadership-Create-Winning-Organization/dp/0071453393 — Other resources Generalist: https://generalistai.com GEN-1.5: https://generalistai.com/blog/gen-1.5 Proprioception: https://en.wikipedia.org/wiki/Proprioception Cutaneous receptor: https://en.wikipedia.org/wiki/Cutaneous_receptor Fukushima nuclear accident: https://en.wikipedia.org/wiki/Fukushima_nuclear_accident The bitter lesson: https://www.cs.utexas.edu/~eunsol/courses/data/bitter_lesson.pdf GEN-1: https://generalistai.com/blog/gen-1 — Where to find Pete Florence LinkedIn: https://www.linkedin.com/in/peteflorence X: https://x.com/peteflorence Website: https://www.peteflorence.com — Production and marketing by penname.co. For inquiries about sponsoring the podcast, email [email protected].
Jaan Tallinn is a founding engineer of Skype and Kazaa, and a co-founder of the Cambridge Centre for the Study of Existential Risk and Future of Life Institute. For more than fifteen years, he has been among the most consistent voices arguing that advanced AI poses an extinction-level risk to humanity.
Liam Fedus and Dogus Cubuk are the co-founders and co-CEOs of Periodic Labs, a startup building “synthesis superintelligence.” In practice, that means an AI system that closes the loop between hypothesis, experiment, and learning.
Scott Morton is the founder and CEO of Revel, a software platform for testing and controlling complex hardware systems. Before founding the company in 2024, Scott spent nearly a decade at SpaceX building control software for Falcon 9 and Starship. That experience helped him recognize a broader problem: while rockets, nuclear systems, supersonic aircraft, and other advanced machines have grown increasingly sophisticated, the software used to test and control them is often fragmented and decades old. Revel was created to close that gap. The company has raised $180 million, was reportedly valued at just over $1 billion, and counts Impulse Space and Radiant Nuclear among its customers. Its platform scales from small benchtop tests to industrial systems with hundreds of thousands of telemetry channels. Revel has also created its own programming language, RevelCode, designed to combine performance and accessibility with the runtime safety required for high-stakes physical systems.
Farooq Malik is the co-founder and CEO of Rain, a financial infrastructure company powered by stablecoins. Growing up in an immigrant family, Farooq saw firsthand the friction involved in moving money across borders. Alongside co-founder Charles Yoo-Naut, Farooq spent years building infrastructure before stablecoins became mainstream, betting that tokenized money would eventually become a foundational layer of the global financial system. Today, Rain powers card issuance, payments, and other financial products built on stablecoin rails, helping companies move money faster and operate across markets.